JPX · 4570.T
Immuno-Biological Laboratories Co., Ltd.
¥1,027-¥12 (-1.15%)
Immuno-Biological Laboratories Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.12% below the high.
Loading market information…
JPX · 4572.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Carna Biosciences, Inc.’s next earnings report is currently expected on Nov 6, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Carna Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥1,027-¥12 (-1.15%)
Immuno-Biological Laboratories Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.12% below the high.
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
¥212-¥2 (-0.93%)
Soiken Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.77% below the high.
¥559¥0 (0.0%)
Kringle Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.56% below the high.
¥64-¥2 (-3.03%)
Ribomic Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
¥215+¥1 (+0.47%)
Trans Genic Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
¥59-¥2 (-3.28%)
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
¥591+¥4 (+0.68%)
Human Metabolome Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.85% below the high.
